Current advances in the application of nanomedicine in bladder cancer

Zhang, Chi; Zhao, Jiang; Wang, Weihao; Geng, Huanhuan; Wang, Yinzhe; Gao, Baofeng

doi:10.1016/j.biopha.2022.114062

Cited by 17 publications

(9 citation statements)

References 246 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…94,95 In addition, the existing drug delivery vectors have a poor ability to specifically target and identify bladder tumors, low drug permeability, short drug retention and action time, and uncontrollable drug release time. 96 Nanomaterials have physical and chemical properties such as small size, good biocompatibility, and easy surface modification. Nanomaterials can be used as drug delivery carriers to design the size of nanomaterials according to the required dose of therapeutic drugs.…”

Section: Nanomaterials In Drug Delivery For Bc Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Application of nanotechnology in bladder cancer diagnosis and therapeutic drug delivery

Zhu

Weng

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Section: Nanomaterials In Drug Delivery For Bc Treatmentmentioning

confidence: 99%

Section: Nanomaterials In Drug Delivery For Bc Treatmentmentioning

confidence: 99%

Application of nanotechnology in bladder cancer diagnosis and therapeutic drug delivery

Zhu

Weng

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

“…Multiple investigations have demonstrated the promising potential of using nanotechnology in the treatment of BC, and as a result, scientists are increasingly combining nanotechnology with traditional therapeutic approaches to address the various obstacles currently encountered when dealing with this disease 3 …”

Section: Using Nanomedicine For Bladder Cancer Therapymentioning

confidence: 99%

“…There will be approximately 17 200 fatalities and 83 730 new instances of BC in the United States in 2021, according to estimates 2 . BC is expected to have a 27.1% incidence rate and an 8.9% fatality rate in Europe 3 . Smoking is one of the most common risk factors for BC, which is a difficult condition with numerous possible risk factors.…”

Section: Introductionmentioning

confidence: 99%

“…2 BC is expected to have a 27.1% incidence rate and an 8.9% fatality rate in Europe. 3 Smoking is one of the most common risk factors for BC, which is a difficult condition with numerous possible risk factors. Radiation therapy (particularly external radiation therapy for gynecological malignancies), malnutrition, metabolic issues, bladder schistosomiasis, and persistent urinary tract infections are all major risk factors.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

miRNAs involvement in the etiology and targeted therapy of bladder cancer: Interaction between signaling pathway

Sharma,

Malviya

2023

Precision Medical Sciences

View full text Add to dashboard Cite

Bladder cancer (BC) accounts for roughly 3% of all cancer diagnoses in developed countries. The prognosis could be improved significantly if the cancer is detected and classified as either muscle‐invasive bladder cancer (MIBC) or non‐muscle‐invasive bladder cancer (NMIBC) as promptly as possible. A potential ray of hope for the treatment of BC has emerged with the rapid development of nanomedicine and microRNAs (miRNAs), which promise to have fewer adverse effects, more tumor‐inhibitory effects, and decreased drug resistance. The complex interplay between hereditary and environmental variables is the root cause of this malignancy. Gene expression can be regulated by miRNAs, which are small, non‐coding RNAs that can either prevent the translation of protein‐coding genes or cleave RNA transcripts at certain locations. Elevated genomics has enabled a more extensive investigation of miRNAs whose expression is considerably different in BC patients compared to healthy volunteers or between BC tumor tissues and peripheral tissues. miRNAs have recently been discovered to be important regulators of BC cell carcinogenicity. Inaccurate diagnoses and prolonged treatment delays are more likely to occur due to the current diagnostic process such as lack of sensitivity and specificity and poor image quality. Patients now have access to a plethora of treatment options, including but not limited to surgery, chemotherapy, immunotherapy, gene therapy, and other innovative medicines, and in some cases, combination therapies. BC is one of the deadliest and most disabling malignancies affecting the urinary tract. Cancer of the urinary bladder has a terrible propensity for being fatal. BC is an intricate illness whose development can be affected by multiple parameters. Standard treatments for BC increase prognosis and survival, although recurrence is a major concern for patients. miRNAs are naturally occurring, small RNA molecules that have been linked to cancer through their expression being dysregulated. miRNAs modulate many cellular activities including proliferation, migration, differentiation, and apoptosis. MiRNA dysregulation is recognized in BC, and miRNAs are used as diagnostic and prognostic indicators. However, this manuscript discusses the recent progress made in nanomedicine and the function of miRNAs in the pathogenesis and targeted therapy of BC.

show abstract